Related Experiment Video

Updated: Jun 10, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells

Kim Mai Huynh1, Jae-Won Soh, Rupesh Dash

  • 1Ilsong Institute of Life Science, Hallym University, Kyonggi-do, Republic of Korea.

Journal of Cellular Physiology
|July 27, 2010
PubMed

Insights

Cancer therapy using terminal differentiation involves down-regulating the FOXM1 transcription factor. This process, driven by PKCα and c-Myc suppression, inhibits melanoma cell growth and proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Terminal differentiation is a promising, less toxic cancer therapy strategy.
  • Interferon-beta (IFN-β) plus mezerein (MEZ) induce terminal differentiation in human metastatic melanoma cells, causing irreversible growth arrest.
  • Down-regulation of Forkhead box M1 (FOXM1) is observed during this differentiation process, potentially inhibiting cell cycle progression.

Purpose of the Study:

  • To elucidate the mechanism of FOXM1 down-regulation during IFN-β plus MEZ-induced terminal differentiation.
  • To investigate the physiological role of FOXM1 in this differentiation process.

Main Methods:

  • Genetic and pharmacological approaches were used to study FOXM1 regulation.
  • Protein kinase C alpha (PKCα) activation and its role in FOXM1 down-regulation were assessed.
  • Promoter analysis, including mutated E-box, and in vitro/in vivo binding assays were performed to confirm c-Myc's role.
  • The effect of c-Myc reduction and Mad1 overexpression on FOXM1 was evaluated.
  • FOXM1 overexpression was used to assess its impact on cell cycle gene expression and cell cycle phase distribution.

Main Results:

  • MEZ treatment activates PKCα, leading to FOXM1 down-regulation.
  • Co-treatment with IFN-β plus MEZ enhances the PKCα-mediated effect on FOXM1.
  • Direct binding of c-Myc to the FOXM1 promoter was confirmed, indicating c-Myc regulates FOXM1 expression.
  • IFN-β plus MEZ treatment results in c-Myc reduction and Mad1 overexpression, causing sustained FOXM1 suppression.
  • Restoring FOXM1 expression re-established cell cycle-associated gene expression and increased S-phase cells.

Conclusions:

  • FOXM1 down-regulation, mediated by PKCα activation and subsequent c-Myc suppression, is a critical event in promoting growth inhibition during melanoma terminal differentiation.
  • This study provides a mechanistic model for how IFN-β plus MEZ induce terminal differentiation and inhibit cancer cell proliferation.

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation07:00

Dual Effects of Melanoma Cell-derived Factors on Bone Marrow Adipocytes Differentiation

Published on: August 23, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...